PRESS RELEASES
National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy

October 13, 2020

EVENTS
Jefferies London Healthcare Conference

NOV 19, 2020, 6:45PM GMT

Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal

HIGHLIGHTS

CBS Dallas-Ft. Worth: North Texas Doctors Testing Drug As Promising Treatment For Severe COVID-19 Complications

October 22, 2020

KXAN: Austin hospitals to help test new COVID-19 treatment

October 15, 2020

Reuters: NIH starts clinical trial testing antibody treatments in COVID-19 patients

October 13, 2020

Genetic Engineering News upgraded LENZ on its COVID-19 Candidate lists from “Keeping an Eye On” to “Definitely Maybe.”

August 28, 2020

Covid-19 Clinical Trials Continue to Rise in Brazil

August 27, 2020

Empowered Patient Podcast: Preventing Cytokine Storm and Relevance to Treating COVID-19 with Dr. Cameron Durrant Humanigen

August 17, 2020

Snowballing research preps avalanche to bury COVID-19

July 2, 2020

Jefferies 2020 Healthcare Conference

June 4, 2020 (Registration required)

Humanigen CEO discusses 71.8 million dollar financing

June 3, 2020

Humanigen announces pricing of $72M private placement as it advances lenzilumab to treat cytokine storm in coronavirus patients

June 2, 2020

Full interview: Humanigen exploring potential therapeutic for lung damage arising from Coronavirus

March 10, 2020

National Geographic: Here’s what coronavirus does to the body

February 18, 2020

Humanigen CEO Interview Podcast at The Wall Street Analyzer

October 28, 2019

Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite

October 23, 2019

Humanigen Live Investor Presentation

October 10, 2019 (Requires free account at virtualinvestorconferences.com)

Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients

July 22, 2019

Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich

July 22, 2019

Humanigen teams up with Kite to treat a type of lymphoma cancer

June 10, 2019

Humanigen's therapy to reduce cancer-treatment side effects highlighted in premier hematology journal

May 17, 2019

Humanigen unveils promising results from Ifabotuzumab Phase I study at the American Association for Cancer Research's annual meeting

April 1, 2019

Humanigen's new data show increase in mice survival with lenzilumab

March 28, 2019

Humanigen presents new study showing lenzilumab's potential to fight tumors

March 22, 2019

Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference

February 25, 2019

Humanigen has gleaned 'significant' interest from potential partners from its data presentation

February 11, 2019

Humanigen new research shows encouraging results for cancer treatment using Car-T

December 5, 2018

Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer

June 9, 2018

Humanigen CEO Speaks with OTC Markets About Strategy to Optimize Car-T Therapy

Cure Brain Cancer Foundation (Australia) Highlights Ifabotuzumab Clinical Trial for GBM

March 1, 2018

Immunotherapy: The Promise and Perils of a New Generation of Cancer Treatments (Stat eBook)

Spring 2017

Axicabtagene Ciloleucel CAR T-Cell Therapy Paper Notes GM-CSF as Biomarker Significantly Associated with Neurotoxicity

December 28, 2017

Cancer Researchers Learn More About Toxic Side Effects of New Treatments

October 12, 2017

Editorial in Blood Journal

by Omar Ahmed

CAR-T–cell neurotoxicity: hope is on the horizon

  • Twitter

©2020 Humanigen, Inc.  All rights reserved